TP53 and neoplasm: Notably, the tumor focus at baseline with IDC-P histology demonstrated the most resistance to therapy, harboring homozygous inactivation of both TP53 and PTEN. Recent reports have also linked prostate ductal and intraductal pathologies to somatic and/or germline alterations affecting the homologous recombination genes ATM, BRCA1, and BRCA226–28.